drugset / Trial / NCT02522208
Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydralazine | Small molecule | 37.5 mg | — |
| Subject | Hydralazine | Small molecule | 75 mg | — |
| Subject | Isosorbide Dinitrate | Other / unclassified | 20 mg | — |
| Subject | Isosorbide Dinitrate | Other / unclassified | 40 mg | — |